SGLT2 inhibitors: β blockers for the kidney?

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 10, 2016, Pages 814-

  Gilbert, Richard E ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ACUTE KIDNEY FAILURE; DISEASE COURSE; DRUG EFFECT; DRUG INHIBITION; ESTIMATED GLOMERULAR FILTRATION RATE; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HEMODYNAMICS; HUMAN; HYPOXIA; KIDNEY DISEASE; KIDNEY TUBULE ABSORPTION; LETTER; MACULA DENSA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RENAL PROTECTION; KIDNEY;

ADRENERGIC BETA-ANTAGONISTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84990057858     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30237-6     Document Type: Letter

References (7)

1. 1 Sattar, N, Preiss, D, Research digest. Lancet Diabetes Endocrinol, 4, 2016, 651.
2. 2 Wanner, C, Inzucchi, SE, Lachin, JM, et al., for the EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
3. 3 Zhang, Y, Thai, K, Kepecs, DM, Gilbert, RE, Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS One, 11, 2016, e0144640.
4. 4 Hansell, P, Welch, WJ, Blantz, RC, Palm, F, Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension. Clin Exp Pharmacol Physiol 40 (2013), 123–137.
5. 5 Korner, A, Eklof, AC, Celsi, G, Aperia, A, Increased renal metabolism in diabetes: mechanism and functional implications. Diabetes 43 (1994), 629–633.
6. 6 Fine, LG, Norman, JT, Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 74 (2008), 867–872.
7. 7 Bonventre, JV, Can we target tubular damage to prevent renal function decline in diabetes?. Semin Nephrol 32 (2012), 452–462.